STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study

Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Every article behind this summary — 1 article from 1 outlet